Aducanumab (Anti-Amyloid Beta)

Synonyms: BIIB037

Catalog No.A2588 Purity:99%

Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD.

Purity & Quality Control

Batch: Purity: 99% Protein concentration: 10.1mg/ml Endotoxin Level: ＜1EU/mg

Choose Selective Beta Amyloid Inhibitors

Name	Citation	Beta Amyloid	Others
DAPT	366	+++	Notch
RO4929097	115	+++	γ secretase,Notch
Semagacestat (LY450139)	20	+++	Notch
MK-0752	23	++++
Avagacestat (BMS-708163)	22	++++
LY2811376	19	++	BACE1
CRANAD-2	0	++
Hoechst 34580	1	+
Frentizole	0	+
Simufilam	✔
Ginsenoside Rg1	✔	NF-κB
Ginsenoside Re	✔	NF-κB,JNK
Tabersonine hydrochloride	✔
EUK 134	✔

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD.

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	1384260-65-4
Molecular Weight	145.5 kDa
Isotype	Human IgG1
Source	CHO
Purification	AKTA
Sterility	0.2 μM filtered
Formulation	100mMPro-Ac,20mMArg-Ac，pH5.0
Storage (From the date of receipt)	Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.